These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 16302461)

  • 21. Enfuvirtide (Fuzeon).
    Proj Inf Perspect; 2003 Oct; (36):4-5. PubMed ID: 14696566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy.
    Poveda E; Rodés B; Lebel-Binay S; Faudon JL; Jimenez V; Soriano V
    J Clin Virol; 2005 Dec; 34(4):295-301. PubMed ID: 16286053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
    Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
    J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
    Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
    N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Enfuvirtide: the first step for a new strategy of antiretroviral therapy].
    Bottaro EG
    Medicina (B Aires); 2007; 67(2):195-205. PubMed ID: 17593608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
    Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
    Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV fusion and its inhibition in antiretroviral therapy.
    Greenberg M; Cammack N; Salgo M; Smiley L
    Rev Med Virol; 2004; 14(5):321-37. PubMed ID: 15334539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy.
    Poveda E; Briz V; Paraskevis D; Barreiro P; Hatzakis A; Soriano V
    AIDS Res Hum Retroviruses; 2007 Sep; 23(9):1078-82. PubMed ID: 17919101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Enfuvirtide: first drug of a new family of antiretroviral agents].
    Espona M; Ferrández O; Grau S; Carmona A
    Farm Hosp; 2005; 29(6):375-83. PubMed ID: 16433570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy.
    Melby TE; Despirito M; Demasi RA; Heilek G; Thommes JA; Greenberg ML; Graham N
    AIDS; 2007 Nov; 21(18):2537-9. PubMed ID: 18025893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic analysis and natural polymorphisms in HIV-1 gp41 isolates from Maputo City, Mozambique.
    Ismael N; Bila D; Mariani D; Vubil A; Mabunda N; Abreu C; Jani I; Tanuri A
    AIDS Res Hum Retroviruses; 2014 Jun; 30(6):603-9. PubMed ID: 24188582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enfuvirtide is active against HIV type 1 group O.
    Poveda E; Barreiro P; Rodés B; Soriano V
    AIDS Res Hum Retroviruses; 2005 Jun; 21(6):583-5. PubMed ID: 15989465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.
    Charpentier C; Jenabian MA; Piketty C; Karmochkine M; Tisserand P; Laureillard D; Bélec L; Si-Mohamed A; Weiss L
    Scand J Infect Dis; 2011 May; 43(5):373-9. PubMed ID: 21341978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of HIV fusion inhibitors.
    Schneider SE; Bray BL; Mader CJ; Friedrich PE; Anderson MW; Taylor TS; Boshernitzan N; Niemi TE; Fulcher BC; Whight SR; White JM; Greene RJ; Stoltenberg LE; Lichty M
    J Pept Sci; 2005 Nov; 11(11):744-53. PubMed ID: 16130177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The introduction of the fusion inhibitors in the HAART-regimens.
    Hasson H; Castagna A; Clementi M; Menzo S; Danise A; Lazzarin A
    New Microbiol; 2004 Apr; 27(2 Suppl 1):11-6. PubMed ID: 15646060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
    J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enfuvirtide: first fusion inhibitor for treatment of HIV infection.
    Jamjian MC; McNicholl IR
    Am J Health Syst Pharm; 2004 Jun; 61(12):1242-7. PubMed ID: 15259753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes.
    Covens K; Kabeya K; Schrooten Y; Dekeersmaeker N; Van Wijngaerden E; Vandamme AM; De Wit S; Van Laethem K
    J Clin Virol; 2009 Apr; 44(4):325-8. PubMed ID: 19237313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of HIV type 1 gp41 and enfuvirtide susceptibility among men in the United States who were HIV infected prior to availability of HIV entry inhibitors.
    Hudelson SE; Marlowe N; Huang W; Bruce R; Church JD; Husnik M; Donnell D; Coates T; Jackson JB; Chesney M; Koblin B; Eshleman SH
    AIDS Res Hum Retroviruses; 2009 Jul; 25(7):701-5. PubMed ID: 19552592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.
    Sista PR; Melby T; Davison D; Jin L; Mosier S; Mink M; Nelson EL; DeMasi R; Cammack N; Salgo MP; Matthews TJ; Greenberg ML
    AIDS; 2004 Sep; 18(13):1787-94. PubMed ID: 15316339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.